Back to News
Market Impact: 0.15
Cramer Says It's Time To Buy The Dip on JNJ
Source: 247wallst.com
Analyst InsightsHealthcare & BiotechInvestor Sentiment & Positioning
Jim Cramer urged investors to buy Johnson & Johnson shares during a mid-session decline, expressing a positive near-term view on the stock. The commentary may modestly support retail investor sentiment but does not include new company fundamentals, earnings, or guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
JNJ0.35
More News
- J&J prostate cancer drug shows promising tumor responses in early trial
- What we want to see when this data center stock reports earnings next week
- Next week brings major risks for the stock market, just as the AI trade keeps faltering
- AI Doubts Spread Cracks in Equities, Credit Markets: Evening Briefing Americas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense Pricing: What Public Contract Data Shows in 2026
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market